Shopping Cart 0
Cart Subtotal
USD 0

iTeos Therapeutics SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

iTeos Therapeutics SA (iTeos) is a biotechnology company that develops novel cancer immunotherapies. The company's pipeline products include small molecule immunomodulators targeting IDO1, A2A, immune check points, STING agonist, and antibodies directed to TIGIT and Galectin 3. It also develops proprietary antibody and small molecules that aim immunosuppressive pathways. iTeos' immunotherapies stimulate the immune system that targets tumors using a platform to identify rational combinations of immunotherapies and novel targets. The company also develops ex vivo screening assays based on different types of human samples to execute gene modulation, metabolomics library screening and expression profiling to identify novel immunosuppressive mechanisms. iTeos is headquartered in Gosselies, Belgium.

iTeos Therapeutics SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

iTeos Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

iTeos Therapeutics Raises USD75 Million in Series B Financing 10

iTeos Therapeutics Raises USD 4 Million In Series A Financing 12

Partnerships 14

Cristal Therapeutics Enters into Agreement with iTeos Therapeutics 14

iTeos Therapeutics Enters into Agreement with Adimab 15

Licensing Agreements 16

iTeos Therapeutics Enters into Licensing Agreement with Pfizer 16

iTeos Therapeutics Receives Rights to IDO1 and TDO2 from Ludwig Institute for Cancer Research 17

iTeos Therapeutics SA-Key Competitors 18

iTeos Therapeutics SA-Key Employees 19

iTeos Therapeutics SA-Locations And Subsidiaries 20

Head Office 20

Recent Developments 21

Corporate Communications 21

Jul 03, 2018: iTeos Therapeutics Names Scott Chappel As Chief Scientific Officer 21

Jun 27, 2018: iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director 22

Jun 29, 2017: iTeos Therapeutics Appoints Mohamed Ragab, M.D. as Vice President, Corporate Development 23

Product News 24

11/06/2017: iTeos Therapeutics to Present New Data at Upcoming 2017 SITC Annual Meeting 24

Clinical Trials 25

Feb 09, 2018: iTeos Therapeutics Provides Update on its IDO1 Inhibitor EOS200271 at Molecular Medicine Tri-Conference 25

Feb 09, 2018: iTeos Therapeutics to Present New Preclinical Data from Anti-TIGIT Antibody Program EOS884448 at Molecular Medicine Tri-Conference 26

Jul 28, 2017: iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region 27

Apr 03, 2017: iTeos Therapeutics: iTeos Therapeutics to Present Data for Novel A2A Receptor Antagonist at American Association for Cancer Research Annual Meeting 28

Appendix 29

Methodology 29

About GlobalData 29

Contact Us 29

Disclaimer 29


List Of Figure

List of Figures

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Key Facts 2

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

iTeos Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

iTeos Therapeutics SA, Deals By Therapy Area, 2012 to YTD 2018 8

iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

iTeos Therapeutics Raises USD75 Million in Series B Financing 10

iTeos Therapeutics Raises USD 4 Million In Series A Financing 12

Cristal Therapeutics Enters into Agreement with iTeos Therapeutics 14

iTeos Therapeutics Enters into Agreement with Adimab 15

iTeos Therapeutics Enters into Licensing Agreement with Pfizer 16

iTeos Therapeutics Receives Rights to IDO1 and TDO2 from Ludwig Institute for Cancer Research 17

iTeos Therapeutics SA, Key Competitors 18

iTeos Therapeutics SA, Key Employees 19

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

iTeos Therapeutics SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.